Eintrag weiter verarbeiten
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies...
Gespeichert in:
| Zeitschriftentitel: | International Journal of Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , |
| In: | International Journal of Cancer, 143, 2018, 3, S. 699-708 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Sun, Zimin Liu, Huilan Luo, Chenhui Geng, Liangquan Zheng, Changcheng Tang, Baolin Zhu, Xiaoyu Tong, Juan Wang, Xingbing Ding, Kaiyang Wan, Xiang Zhang, Lei Yao, Wen Song, Kaiding Zhang, Xuhan Wu, Yue Yang, Huizhi Han, Yongsheng Liu, Xin Zhu, Weibo Wu, Jingsheng Wang, Zuyi Sun, Zimin Liu, Huilan Luo, Chenhui Geng, Liangquan Zheng, Changcheng Tang, Baolin Zhu, Xiaoyu Tong, Juan Wang, Xingbing Ding, Kaiyang Wan, Xiang Zhang, Lei Yao, Wen Song, Kaiding Zhang, Xuhan Wu, Yue Yang, Huizhi Han, Yongsheng Liu, Xin Zhu, Weibo Wu, Jingsheng Wang, Zuyi |
|---|---|
| author |
Sun, Zimin Liu, Huilan Luo, Chenhui Geng, Liangquan Zheng, Changcheng Tang, Baolin Zhu, Xiaoyu Tong, Juan Wang, Xingbing Ding, Kaiyang Wan, Xiang Zhang, Lei Yao, Wen Song, Kaiding Zhang, Xuhan Wu, Yue Yang, Huizhi Han, Yongsheng Liu, Xin Zhu, Weibo Wu, Jingsheng Wang, Zuyi |
| spellingShingle |
Sun, Zimin Liu, Huilan Luo, Chenhui Geng, Liangquan Zheng, Changcheng Tang, Baolin Zhu, Xiaoyu Tong, Juan Wang, Xingbing Ding, Kaiyang Wan, Xiang Zhang, Lei Yao, Wen Song, Kaiding Zhang, Xuhan Wu, Yue Yang, Huizhi Han, Yongsheng Liu, Xin Zhu, Weibo Wu, Jingsheng Wang, Zuyi International Journal of Cancer Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study Cancer Research Oncology |
| author_sort |
sun, zimin |
| spelling |
Sun, Zimin Liu, Huilan Luo, Chenhui Geng, Liangquan Zheng, Changcheng Tang, Baolin Zhu, Xiaoyu Tong, Juan Wang, Xingbing Ding, Kaiyang Wan, Xiang Zhang, Lei Yao, Wen Song, Kaiding Zhang, Xuhan Wu, Yue Yang, Huizhi Han, Yongsheng Liu, Xin Zhu, Weibo Wu, Jingsheng Wang, Zuyi 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.31339 <jats:p>Cord blood transplantation (CBT) is an effective option for treating hematological malignancies, but graft failure (GF) remains the primary cause of therapy failure. Thus, based on myeloablative conditioning (MAC) of busulfan with cyclophosphamide (Bu/Cy) or total body irradiation with Cy (TBI/Cy), fludarabine (Flu) was added to Bu/Cy and cytarabine (CA) to TBI/Cy for a modified myeloablative conditioning (MMAC). To compare the prognosis of MMAC with MAC, we conducted a retrospective study including 58 patients who underwent CBT with MAC or MMAC from 2000 to 2011. Neutrophil and platelet engraftment rate, overall survival (OS) and disease free survival (DFS) were significantly higher in the MMAC group (adjusted hazard ratio [HR], 2.58, 2.43, 0.36 and 0.37; <jats:italic>p</jats:italic> < 0.01, <jats:italic>p</jats:italic> = 0.01, <jats:italic>p</jats:italic> = 0.02 and <jats:italic>p</jats:italic> = 0.02, separately). Nonrelapse mortality (NRM) was comparable (<jats:italic>p</jats:italic> = 0.183). To validate the outcomes noted in the MMAC group, we conducted a prospective single‐arm clinical trial including 188 patients who underwent CBT with MMAC from 2011 to 2015. Engraftment rate, survival and NRM of the MMAC group in the prospective trail (MMAC‐P) were similar to the MMAC group in the retrospective study (MMAC‐R). This study is the first to demonstrate the superiority of MMAC to MAC in CBT for hematological malignancies.</jats:p> Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study International Journal of Cancer |
| doi_str_mv |
10.1002/ijc.31339 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMzEzMzk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMzEzMzk |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Wiley, 2018 |
| imprint_str_mv |
Wiley, 2018 |
| issn |
0020-7136 1097-0215 |
| issn_str_mv |
0020-7136 1097-0215 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
sun2018betteroutcomesofmodifiedmyeloablativeconditioningwithoutantithymocyteglobulinversusmyeloablativeconditioningincordbloodtransplantationforhematologicalmalignanciesaretrospectivedevelopmentandaprospectivevalidationstudy |
| publishDateSort |
2018 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
International Journal of Cancer |
| source_id |
49 |
| title |
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_unstemmed |
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_full |
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_fullStr |
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_full_unstemmed |
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_short |
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_sort |
better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: a retrospective (development) and a prospective (validation) study |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1002/ijc.31339 |
| publishDate |
2018 |
| physical |
699-708 |
| description |
<jats:p>Cord blood transplantation (CBT) is an effective option for treating hematological malignancies, but graft failure (GF) remains the primary cause of therapy failure. Thus, based on myeloablative conditioning (MAC) of busulfan with cyclophosphamide (Bu/Cy) or total body irradiation with Cy (TBI/Cy), fludarabine (Flu) was added to Bu/Cy and cytarabine (CA) to TBI/Cy for a modified myeloablative conditioning (MMAC). To compare the prognosis of MMAC with MAC, we conducted a retrospective study including 58 patients who underwent CBT with MAC or MMAC from 2000 to 2011. Neutrophil and platelet engraftment rate, overall survival (OS) and disease free survival (DFS) were significantly higher in the MMAC group (adjusted hazard ratio [HR], 2.58, 2.43, 0.36 and 0.37; <jats:italic>p</jats:italic> < 0.01, <jats:italic>p</jats:italic> = 0.01, <jats:italic>p</jats:italic> = 0.02 and <jats:italic>p</jats:italic> = 0.02, separately). Nonrelapse mortality (NRM) was comparable (<jats:italic>p</jats:italic> = 0.183). To validate the outcomes noted in the MMAC group, we conducted a prospective single‐arm clinical trial including 188 patients who underwent CBT with MMAC from 2011 to 2015. Engraftment rate, survival and NRM of the MMAC group in the prospective trail (MMAC‐P) were similar to the MMAC group in the retrospective study (MMAC‐R). This study is the first to demonstrate the superiority of MMAC to MAC in CBT for hematological malignancies.</jats:p> |
| container_issue |
3 |
| container_start_page |
699 |
| container_title |
International Journal of Cancer |
| container_volume |
143 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339300740759552 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:45:56.723Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Better+outcomes+of+modified+myeloablative+conditioning+without+antithymocyte+globulin+versus+myeloablative+conditioning+in+cord+blood+transplantation+for+hematological+malignancies%3A+A+retrospective+%28development%29+and+a+prospective+%28validation%29+study&rft.date=2018-08-01&genre=article&issn=1097-0215&volume=143&issue=3&spage=699&epage=708&pages=699-708&jtitle=International+Journal+of+Cancer&atitle=Better+outcomes+of+modified+myeloablative+conditioning+without+antithymocyte+globulin+versus+myeloablative+conditioning+in+cord+blood+transplantation+for+hematological+malignancies%3A+A+retrospective+%28development%29+and+a+prospective+%28validation%29+study&aulast=Wang&aufirst=Zuyi&rft_id=info%3Adoi%2F10.1002%2Fijc.31339&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339300740759552 |
| author | Sun, Zimin, Liu, Huilan, Luo, Chenhui, Geng, Liangquan, Zheng, Changcheng, Tang, Baolin, Zhu, Xiaoyu, Tong, Juan, Wang, Xingbing, Ding, Kaiyang, Wan, Xiang, Zhang, Lei, Yao, Wen, Song, Kaiding, Zhang, Xuhan, Wu, Yue, Yang, Huizhi, Han, Yongsheng, Liu, Xin, Zhu, Weibo, Wu, Jingsheng, Wang, Zuyi |
| author_facet | Sun, Zimin, Liu, Huilan, Luo, Chenhui, Geng, Liangquan, Zheng, Changcheng, Tang, Baolin, Zhu, Xiaoyu, Tong, Juan, Wang, Xingbing, Ding, Kaiyang, Wan, Xiang, Zhang, Lei, Yao, Wen, Song, Kaiding, Zhang, Xuhan, Wu, Yue, Yang, Huizhi, Han, Yongsheng, Liu, Xin, Zhu, Weibo, Wu, Jingsheng, Wang, Zuyi, Sun, Zimin, Liu, Huilan, Luo, Chenhui, Geng, Liangquan, Zheng, Changcheng, Tang, Baolin, Zhu, Xiaoyu, Tong, Juan, Wang, Xingbing, Ding, Kaiyang, Wan, Xiang, Zhang, Lei, Yao, Wen, Song, Kaiding, Zhang, Xuhan, Wu, Yue, Yang, Huizhi, Han, Yongsheng, Liu, Xin, Zhu, Weibo, Wu, Jingsheng, Wang, Zuyi |
| author_sort | sun, zimin |
| container_issue | 3 |
| container_start_page | 699 |
| container_title | International Journal of Cancer |
| container_volume | 143 |
| description | <jats:p>Cord blood transplantation (CBT) is an effective option for treating hematological malignancies, but graft failure (GF) remains the primary cause of therapy failure. Thus, based on myeloablative conditioning (MAC) of busulfan with cyclophosphamide (Bu/Cy) or total body irradiation with Cy (TBI/Cy), fludarabine (Flu) was added to Bu/Cy and cytarabine (CA) to TBI/Cy for a modified myeloablative conditioning (MMAC). To compare the prognosis of MMAC with MAC, we conducted a retrospective study including 58 patients who underwent CBT with MAC or MMAC from 2000 to 2011. Neutrophil and platelet engraftment rate, overall survival (OS) and disease free survival (DFS) were significantly higher in the MMAC group (adjusted hazard ratio [HR], 2.58, 2.43, 0.36 and 0.37; <jats:italic>p</jats:italic> < 0.01, <jats:italic>p</jats:italic> = 0.01, <jats:italic>p</jats:italic> = 0.02 and <jats:italic>p</jats:italic> = 0.02, separately). Nonrelapse mortality (NRM) was comparable (<jats:italic>p</jats:italic> = 0.183). To validate the outcomes noted in the MMAC group, we conducted a prospective single‐arm clinical trial including 188 patients who underwent CBT with MMAC from 2011 to 2015. Engraftment rate, survival and NRM of the MMAC group in the prospective trail (MMAC‐P) were similar to the MMAC group in the retrospective study (MMAC‐R). This study is the first to demonstrate the superiority of MMAC to MAC in CBT for hematological malignancies.</jats:p> |
| doi_str_mv | 10.1002/ijc.31339 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMzEzMzk |
| imprint | Wiley, 2018 |
| imprint_str_mv | Wiley, 2018 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0020-7136, 1097-0215 |
| issn_str_mv | 0020-7136, 1097-0215 |
| language | English |
| last_indexed | 2024-03-01T15:45:56.723Z |
| match_str | sun2018betteroutcomesofmodifiedmyeloablativeconditioningwithoutantithymocyteglobulinversusmyeloablativeconditioningincordbloodtransplantationforhematologicalmalignanciesaretrospectivedevelopmentandaprospectivevalidationstudy |
| mega_collection | Wiley (CrossRef) |
| physical | 699-708 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | International Journal of Cancer |
| source_id | 49 |
| spelling | Sun, Zimin Liu, Huilan Luo, Chenhui Geng, Liangquan Zheng, Changcheng Tang, Baolin Zhu, Xiaoyu Tong, Juan Wang, Xingbing Ding, Kaiyang Wan, Xiang Zhang, Lei Yao, Wen Song, Kaiding Zhang, Xuhan Wu, Yue Yang, Huizhi Han, Yongsheng Liu, Xin Zhu, Weibo Wu, Jingsheng Wang, Zuyi 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.31339 <jats:p>Cord blood transplantation (CBT) is an effective option for treating hematological malignancies, but graft failure (GF) remains the primary cause of therapy failure. Thus, based on myeloablative conditioning (MAC) of busulfan with cyclophosphamide (Bu/Cy) or total body irradiation with Cy (TBI/Cy), fludarabine (Flu) was added to Bu/Cy and cytarabine (CA) to TBI/Cy for a modified myeloablative conditioning (MMAC). To compare the prognosis of MMAC with MAC, we conducted a retrospective study including 58 patients who underwent CBT with MAC or MMAC from 2000 to 2011. Neutrophil and platelet engraftment rate, overall survival (OS) and disease free survival (DFS) were significantly higher in the MMAC group (adjusted hazard ratio [HR], 2.58, 2.43, 0.36 and 0.37; <jats:italic>p</jats:italic> < 0.01, <jats:italic>p</jats:italic> = 0.01, <jats:italic>p</jats:italic> = 0.02 and <jats:italic>p</jats:italic> = 0.02, separately). Nonrelapse mortality (NRM) was comparable (<jats:italic>p</jats:italic> = 0.183). To validate the outcomes noted in the MMAC group, we conducted a prospective single‐arm clinical trial including 188 patients who underwent CBT with MMAC from 2011 to 2015. Engraftment rate, survival and NRM of the MMAC group in the prospective trail (MMAC‐P) were similar to the MMAC group in the retrospective study (MMAC‐R). This study is the first to demonstrate the superiority of MMAC to MAC in CBT for hematological malignancies.</jats:p> Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study International Journal of Cancer |
| spellingShingle | Sun, Zimin, Liu, Huilan, Luo, Chenhui, Geng, Liangquan, Zheng, Changcheng, Tang, Baolin, Zhu, Xiaoyu, Tong, Juan, Wang, Xingbing, Ding, Kaiyang, Wan, Xiang, Zhang, Lei, Yao, Wen, Song, Kaiding, Zhang, Xuhan, Wu, Yue, Yang, Huizhi, Han, Yongsheng, Liu, Xin, Zhu, Weibo, Wu, Jingsheng, Wang, Zuyi, International Journal of Cancer, Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study, Cancer Research, Oncology |
| title | Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_full | Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_fullStr | Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_full_unstemmed | Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_short | Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| title_sort | better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: a retrospective (development) and a prospective (validation) study |
| title_unstemmed | Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1002/ijc.31339 |